Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-064005
Filing Date
2025-05-06
Accepted
2025-05-06 09:00:20
Documents
59
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cogt-20250331.htm   iXBRL 10-Q 1606177
2 EX-5.1 cogt-ex5_1.htm EX-5.1 8324
3 EX-31.1 cogt-ex31_1.htm EX-31.1 14750
4 EX-31.2 cogt-ex31_2.htm EX-31.2 14738
5 EX-32.1 cogt-ex32_1.htm EX-32.1 9839
6 EX-32.2 cogt-ex32_2.htm EX-32.2 9814
7 GRAPHIC img159288598_0.jpg GRAPHIC 211871
8 GRAPHIC img229944979_0.jpg GRAPHIC 3456
  Complete submission text file 0000950170-25-064005.txt   7154965

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cogt-20250331.xsd EX-101.SCH 957462
62 EXTRACTED XBRL INSTANCE DOCUMENT cogt-20250331_htm.xml XML 1038594
Mailing Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451
Business Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

EIN.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38443 | Film No.: 25915571
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)